PUBLISHER: Grand View Research | PRODUCT CODE: 1869734
PUBLISHER: Grand View Research | PRODUCT CODE: 1869734
The U.S. peripheral nerve stimulators market size was estimated at USD 105.14 million in 2024 and is projected to reach USD 253.36 million by 2033, growing at a CAGR of 10.43% from 2025 to 2033. The U.S. peripheral nerve stimulators industry is primarily driven by the rising prevalence of chronic pain conditions and increasing demand for minimally invasive, targeted pain management therapies, and the growing shift toward non-opioid therapies.
Growing awareness among healthcare providers and patients about the effectiveness of peripheral nerve stimulation in improving quality of life is fueling adoption. Technological advancements, including implantable systems, wearable stimulators, and enhanced programmable features, further propel market growth. The expansion of outpatient and ambulatory surgery centers, favorable reimbursement policies, and an aging population with higher surgical volumes contribute to the sustained momentum of the market.
Rising prevalence of chronic diseases continues to drive growth in the U.S. peripheral nerve stimulators industry, as patients with conditions such as diabetes, obesity, hypertension, asthma, and chronic pain increasingly require targeted, long-term pain management solutions. Peripheral nerve stimulators offer minimally invasive options to alleviate pain associated with these illnesses, improving patient outcomes and quality of life.
For instance, in April 2025, Health System Tracker highlighted that the U.S. has a higher rate of chronic diseases compared to peer nations, with over twice as many people affected by obesity and diabetes, 1.7 times more with asthma, and an overall higher burden of depression. This elevated prevalence of chronic conditions not only increases demand for advanced pain management therapies but also underscores the growing need for effective, clinically proven peripheral nerve stimulation solutions. According to the Pan American Health Organization's (PAHO) report, in July 2025, cardiovascular diseases led with 2.16 million deaths, followed by cancer (1.37 million), diabetes (over 420,000), and chronic respiratory conditions (more than 416,000). Suicide, the fourth leading cause of death among youth aged 15-29, claimed 100,760 lives.
U.S. Peripheral Nerve Stimulators Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. peripheral nerve stimulators market report based on product type, modality, connectivity, application, and end use: